Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

CONCLUSIONS: We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including 2 with baseline CCNE1 mRNA overexpression. Future studies will determine whether CCNE1 overexpression is a predictive biomarker for adavosertib.PMID:33863809 | DOI:10.1158/1078-0432.CCR-21-0329

Source: Clinical Cancer Research - April 17, 2021 Category: Cancer & Oncology Authors: Naoko Takebe Abdul Rafeh Naqash Geraldine O'Sullivan Coyne Shivaani Kummar Khanh T Do Ashley Bruns Lamin Juwara Jennifer Zlott Lawrence Rubinstein Richard L Piekarz Elad Sharon Howard Streicher Arjun Mittra Sarah B Miller Jiuping Ji Deborah F Wilsker Robe Source Type: research